Revised SPC: Ocrevus (ocrelizumab) 300mg concentrate for solution for infusion
SPC updated to note that symptoms of infusion-related reactions reported in the post-marketing setting include anaphylaxis.
Source:
electronic Medicines compendium
SPC updated to note that symptoms of infusion-related reactions reported in the post-marketing setting include anaphylaxis.
electronic Medicines compendium